新しい薬疹

出版社： 文光堂
著者：
発行日： 2019-11-10
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784830634710
電子書籍版： 2019-11-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

近年，生物学的製剤や分子標的薬，免疫チェックポイント阻害薬などの薬剤が登場し，従来にはなかった新しいタイプの薬疹が報告されている．本書では様々な原因薬別にその発生機序，症状，対処法について詳細に解説した．臨床写真がふんだんに掲載されており，アトラスとしても利用できる．皮膚科医はもちろん，原因薬剤を処方した一般内科医にも役立つ内容となっており，これまでになかった1冊となった．

目次

  • 序説　薬疹から皮膚有害事象へ

    第I章　薬剤による皮膚有害事象
    A　分子標的薬による皮膚有害事象
    　1　分子標的薬による痤瘡とその治療
    　2　分子標的薬による手足症候群とその治療
    　3　分子標的薬による爪囲炎とその治療
    　4　タキサン系薬剤による皮膚障害
    　COLUMN　抗がん剤漏出の対処法
    B　メラノーマ・リンフォーマ治療薬による皮膚有害事象
    　1　抗PD-1抗体，抗CTLA-4抗体による皮膚障害
    　2　BRAF阻害薬，MEK阻害薬による皮膚障害
    　3　抗CCR4抗体による皮膚障害
    　COLUMN　抗CCR4抗体による光線過敏症
    C　乾癬治療薬による皮膚有害事象
    　1　生物学的製剤による投与時反応
    　2　TNF-α阻害薬による逆説的反応
    　3　生物学的製剤による皮膚感染症
    　4　生物学的製剤による脱毛症
    　COLUMN　急性汎発性発疹性膿疱症と膿疱性乾癬
    　COLUMN　抗IL-4/IL-13受容体抗体による結膜炎
    D　特殊な薬剤による皮膚障害
    　1　DPP-4阻害薬による水疱性類天疱瘡
    　2　漢方薬による皮膚障害
    　3　セツキシマブによるアレルギー
    　4　ヒドロキシクロロキンによる薬疹
    　5　ワルファリンによる皮膚障害
    　COLUMN　G-CSF製剤によるSweet症候群

    第II章　薬剤による特殊な皮膚障害
    　1　近年の薬剤性光線過敏症
    　2　ボリコナゾールによる光線関連皮膚癌
    　3　ハイドロキシウレアによる皮膚潰瘍
    　4　薬剤による皮膚硬化
    　5　メトトレキサートとリンパ増殖異常症
    　6　免疫グロブリン大量静注療法による汗疱状皮疹
    　7　インスリン注射部位の硬結（インスリンボール）
    　COLUMN　苔癬型薬疹：最近の原因薬

    第III章　有害事象の発生機序
    　1　イミキモドの免疫変調作用
    　2　EBウイルス感染症と薬疹
    　3　Stevens-Johnson症候群/中毒性表皮壊死症の免疫異常
    　4　DIHSにおけるウイルス再活性化と自己免疫疾患
    　5　固定薬疹の発症機序－resident memory T細胞を含めて－

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第I章 薬剤による皮膚有害事象

P.8 掲載の参考文献
1) 水谷仁, ほか : 分子標的治療 総論. がん患者に対するアピアランスケアの手引き, 国立がん研究センターがん患者の外見支援に関するガイドライン研究班編, 金原出版, P52-60, 2016
 
2) Braden RL, Anadkat MJ : EGFR inhibitor-induced skin reactions : differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer 24 : 3943-3950, 2016
PubMed
3) 中原剛士 : 上皮成長因子受容体 (Epidermal Growth Factor Receptor : EGFR) 阻害薬による皮膚障害-臨床症状, 治療・対策, 病態・発症機序について. 西日皮 77 : 203-209, 2015
 
4) Kikuchi K, et al : Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. J Dermatol 46 : 18-25, 2019
PubMed
5) Scope A, et al : A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61 : 614-620, 2009
PubMed
6) 山本有紀, ほか : EGFR 阻害薬に起因する皮膚障害の治療手引き-皮膚科・腫瘍内科有志コンセンサス会議からの提案. 臨床医薬 32 : 941-949, 2016
Medical*Online
7) Kiyohara Y, et al : Erlotinib-related skin toxicities : treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol 69 : 463-472, 2013
PubMed
8) 相馬良直 : ステロイド外用剤の副作用. 皮膚臨床 48 : 69-76, 2006
 
9) Lacouture ME, et al : Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28 : 1351-1357, 2010
 
10) Kobayashi Y, et al : Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer : HGCSG1001 study ; J-STEPP. Future Oncol 11 : 617-627, 2015
PubMed
11) Graves JE, et al : Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 55 : 349-353, 2006
PubMed
12) Toda N, et al : Erosive pustular dermatosis of the scalp-like eruption due to gefitinib : case report and review of the literature of alopecia associated with EGFR inhibitors. Dermatology 225 : 18-21, 2012
PubMed
P.13 掲載の参考文献
1) Gressett SM, et al : Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12 : 131-141, 2006
PubMed
2) Riechelmann RP, et al : Sorafenib for metastatic renal cancer : the Princess Margaret experience. Am J Clin Oncol 31 : 182-187, 2008
PubMed
3) Diasio RB : Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Williston Park) 14 : 19-23, 2000
 
4) Autier J, et al : Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 144 : 886-892, 2008
PubMed
5) Yamamoto K, et al : Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). PLoS One 9 : e102110, 2014
PubMed
6) Espinosa Lara P, et al : Hand-Foot Skin Reaction to Regorafenib. Actas Dermosifiliogr 107 : 71-73, 2016
PubMed
7) Chanprapaph K, et al : Multikinase Inhibitor-Induced Hand-Foot Skin Reaction : A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol 17 : 387-402, 2016
PubMed
8) Miller KK, et al : Chemotherapy-induced hand-foot syndrome and nail changes : a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71 : 787-794, 2014
PubMed
9) Porta C, et al : Uncovering Pandora's vase : the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7 : 127-134, 2007
PubMed
10) Lipworth AD, et al : Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia) : focus on sorafenib and sunitinib. Oncology 77 : 257-271, 2009
PubMed
11) Belum VR, et al : Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib : a meta-analysis. Invest New Drugs 31 : 1078-1086, 2013
PubMed
12) Motzer RJ, et al : Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 : 722-731, 2013
PubMed
13) Li J, Gu J : Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients : A systematic review and meta-analysis. Crit Rev Oncol Hematol 119 : 50-58, 2017
PubMed
14) Blum JL, et al : Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 : 485-493, 1999
PubMed
15) Wang E, et al : Hand-foot-skin reaction of grade > 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. Invest New Drugs 37 : 404-414, 2019
 
16) Wang P, et al : Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma : a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol 12 : 1-8, 2018
PubMed
17) Ren Z, et al : Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33 : 894-900, 2015
PubMed
P.18 掲載の参考文献
1) Lemmon MA, Schlessinger J : Cell signaling by receptor tyrosine kinases. Cell 141 : 1117-1134, 2010
PubMed
2) Wee P, Wang Z : Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) 9 : 2017. pii : E52. doi : 10.3390/cancers9050052
 
3) Nanney LB, et al : Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83 : 385-393, 1984
PubMed
4) Nanney LB, et al : Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol 82 : 165-169, 1984
PubMed
5) Miettinen PJ, et al : Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376 : 337-341, 1995
PubMed
6) Sibilia M, Wagner EF : Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269 : 234-238, 1995
PubMed
7) Franzke CW, et al : Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J Exp Med 209 : 1105-1119, 2012
PubMed
8) Normanno N, et al : Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) : simple drugs with a complex mechanism of action? J Cell Physiol 194 : 13-19, 2003
PubMed
9) Capdevila J, et al : Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 35 : 354-363, 2009
PubMed
10) Price TJ, et al : Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT) : a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15 : 569-579, 2014
PubMed
11) Chen KL, et al : Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer. JAMA Dermatol 152 : 340-342, 2016
PubMed
12) Chu CY, et al : Osimertinib : A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist 23 : 891-899, 2018
PubMed
13) Wu YL, et al : Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050) : a randomised, open-label, phase 3 trial. Lancet Oncol 18 : 1454-1466, 2017
PubMed
14) Lichtenberger BM, et al : Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 5 : 199ra111, 2013
PubMed
15) Park K, et al : Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by Staphylococcus epidermidis. J Dermatol Sci 75 : 94-99, 2014
 
16) Albanell J, et al : Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients : histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 : 110-124, 2002
PubMed
17) Dika E, et al : Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol 26 : 232-239, 2016
PubMed
18) Boull C, et al : Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors. Pediatr Dermatol 34 : 90-94, 2017
PubMed
19) Sibaud V, et al : Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol 91 : 584-585, 2011
PubMed
20) Johnston SRD, et al : Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer : ALTERNATIVE. J Clin Oncol 36 : 741-748, 2018
PubMed
21) Kozuki T : Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 46 : 291-298, 2016
PubMed
22) Hachisuka J, et al : Effect of adapalene on cetuximab-induced painful periungual inflammation. J Am Acad Dermatol 64 : e20-e21, 2011
PubMed
23) Shu KY, et al : Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154 : 191-192, 2006
PubMed
P.24 掲載の参考文献
1) Baselga J, Tabernero JM : Weekly docetaxel in breast cancer : applying clinical data to patient therapy. Oncologist 6 (Suppl 3) : 26-29, 2001
 
2) Sibaud V, et al : Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26 : 427-443, 2016
PubMed
3) Childress J, Lokich L : Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 26 : 435-436, 2003
 
4) Chu CY, et al : Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142 : 808-811, 2000
PubMed
5) Karam A, et al : Squamous syringometaplasia associated with docetaxel. Br J Dermatol 146 : 524-525, 2002
PubMed
6) Plummer RS, Shea CR : Dermatopathologic effects of taxane therapy. J Am Acad Dermatol 65 : 592-596, 2011
PubMed
7) Fujii M, et al : Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin-bound paclitaxel. J Dermatol 42 : 1134-1135, 2015
PubMed
8) Remlinger KA : Cutaneous reactions to chemotherapy drugs : the art of consultation. Arch Dermatol 139 : 77-81, 2003
PubMed
9) Bolognia JL, et al : Toxic erythema of chemotherapy : a useful clinical term. J Am Acad Dermatol 59 : 524-529, 2008
PubMed
10) Marks DH, et al : Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events : A Systematic Review. JAMA Dermatol 154 : 1465-1472, 2018
PubMed
11) Akoglu G : Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes. Indian J Pharmacol 46 : 225-227, 2014
PubMed
12) Adachi A, Horikawa T : Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 34 : 473-476, 2007
PubMed
13) Semb KA, et al : Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16 : 3426-3432, 1998
PubMed
14) Farrant PB, et al : Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol 29 : 360-362, 2004
PubMed
15) 久保正英 : タキサンと強皮症様変化. 皮膚臨床 54 (臨増) : 1571-1574, 2012
 
16) Okada K, et al : Glycosaminoglycan and versican deposits in taxane-induced sclerosis. Br J Dermatol 173 : 1054-1058, 2015
PubMed
17) 岡田佳与, ほか : タキサン系抗がん剤による皮膚硬化早期病変におけるバーシカン沈着増加. 臨皮 71 (Suppl) : 153-155, 2017
 
18) Lee C, et al : Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 102 : 179-187, 2009
PubMed
19) Prieto Garcia A, Pineda de la Losa F : Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 20 : 170-171, 2010
PubMed
20) 相原道子 : 乳癌治療薬による皮膚障害. 皮病診療 31 : 664-670, 2009
 
21) 木村盛彦, ほか : 進行・再発乳癌に対するPaclitaxel Weekly投与の臨床経験. 癌と化療 27 : 1703-1708, 2000
Medical*Online
22) Prevezas C, et al : Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 160 : 883-885, 2009
PubMed
23) Munstedt K, et al : Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 5 : 139-143, 1997
PubMed
24) Capriotti K, et al : The risk of nail changes with taxane chemotherapy : a systematic review of the literature and meta-analysis. Br J Dermatol 173 : 842-845, 2015
PubMed
25) Capriotti K, et al : Chemotherapy-associated paronychia treated with 2% povidone-iodine : a series of cases. Cancer Manag Res 9 : 225-228, 2017
PubMed
P.26 掲載の参考文献
1) Vasconcelos I, Schoenegg W : Massive breast necrosis after extravasation of a full anthracycline cycle.BMJ Case Rep : pii : bcr2013201179, doi : 10.1136/bcr-2013-201179, 2013
 
2) Narducci F, et al : Totally implantable venous access port systems and risk factors for complications : a one-year prospective study in a cancer centre. Eur J Surg Oncol 37 : 913-918, 2011
 
3) Mouridsen HT, et al : Treatment of anthracycline extravasation with Savene (dexrazoxane) : results from two prospective clinical multicentre studies. Ann Oncol 18 : 546-550, 2007
PubMed
4) Lipshultz SE, et al : The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 : 145-153, 2004
PubMed
P.34 掲載の参考文献
1) 小野薬品工業オプジーボ(R) 適性使用ガイド
 
2) 小野薬品工業株式会社/ブリストル・マイヤーズスクイブ株式会社 ヤーボイ(R) 点滴静注液 50mg 添付文書
 
3) Sibaud V : Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Am J Clin Dermatol 19 : 345-361, 2018
 
4) Belum VR, et al : Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60 : 12-25, 2016
PubMed
5) Robert C, et al : Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 : 320-330, 2015
PubMed
6) Larkin J, et al : Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373 : 23-34, 2015
 
7) Robert C, et al : Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372 : 2521-2532, 2015
PubMed
8) Hamid O, et al : Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 : 134-144, 2013
PubMed
9) Wolchok JD, et al : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 : 122-133, 2013
PubMed
10) Minkis K, et al : The risk of rash associated with ipilimumab in patients with cancer : a systematic review of the literature and meta-analysis. J Am Acad Dermatol 69 : e121-128, 2013
 
11) Sibaud V, et al : Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28 : 254-263, 2016
PubMed
12) Hwang SJ, et al : Cutaneous adverse events (AEs) of antiprogrammed cell death (PD) -1 therapy in patients with metastatic melanoma : a single-institution cohort. J Am Acad Dermatol 74 : 455-461, 2016
PubMed
13) Belum VR, et al : Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60 : 12-25, 2016
PubMed
14) Nakamura Y, et al : Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab : a multi-institutional retrospective study. J Dermatol 44 : 117-122, 2017
PubMed
15) Gutzmer R, et al : Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75 : 24-32, 2017
PubMed
16) Naidoo J, et al : Autoimmune Bullous Skin Disorders With Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res 4 : 383-389, 2016
PubMed
17) Sheik Ali S, et al : Drug-induced dermatomyositis following ipilimumab therapy : anovel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151 : 195-199, 2015
 
18) Cotliar J, et al : Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2 : 290-293, 2016
PubMed
19) Weber JS, et al : Safety Profile of Nivolumab Monotherapy : A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 35 : 785-792, 2017
PubMed
20) Sibaud V, et al : Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies : clinicopathological findings. J Eur Acad Dermatol Venereol 31 : e464-469, 2017
PubMed
P.41 掲載の参考文献
1) Boada A, et al : Cutaneous toxicities of new treatments for melanoma. Clin Transl Oncol 20 : 1373-1384, 2018
PubMed
2) Macdonald JB, et al : Cutaneous adverse effects of targeted therapies : Part II : Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 72 : 221-236, 2015
PubMed
3) Russo I, et al : A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma : a single-centre experience. Eur J Dermatol 27 : 482-486, 2017
PubMed
4) Piraccini BM, et al : RASopathic alopecia : hair changes associated with vemurafenib therapy. J Am Acad Dermatol 72 : 738-741, 2015
PubMed
5) de Golian E, et al : Cutaneous Complications of Targeted Melanoma Therapy. Curr Treat Options Oncol 17 : 57, 2016
PubMed
6) Parekh V, et al : NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. J Cutan Pathol 46 : 190-194, 2019
PubMed
7) Daud A, Tsai K : Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist 22 : 823-833, 2017
PubMed
P.49 掲載の参考文献
1) Ishida T, et al : CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10 : 5494-5500, 2004
 
2) Ishii T, et al : Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 16 : 1520-1531, 2010
PubMed
3) Ishida T, et al : Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma : A multicenter phase II study. J Clin Oncol 30 : 837-842, 2012
PubMed
4) Ogura M, et al : Multicenter phase II study of mogamulizumab KW-0761, a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 32 : 1157-1163, 2014
PubMed
5) Yonekura K, et al : Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma : cutaneous adverse reactions may predict the prognosis. J Dermatol 41 : 239-244, 2014
PubMed
6) Yonekura K, et al : Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma. Acta Derm Venereol 96 : 1000-1002, 2016
PubMed
7) 米倉健太郎 : 抗CCR4抗体mogamulizumab治療における皮膚障害とその対策. 血液内科 68 : 481-486, 2014
 
8) Tokunaga M, et al : Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. Br J Haematol 181 : 539-542, 2018
PubMed
9) Honda T, et al : Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient. Acta Derm Venereol 95 : 606-607, 2015
 
P.51 掲載の参考文献
1) Yonekura K, et al : Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma : cutaneous adverse reactions may predict the prognosis. J Dermatol 41 : 239-244, 2014
PubMed
2) Honda T, et al : Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient. Acta Derm Venereol 95 : 606-607, 2015
 
3) Ishida T, et al : Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104 : 647-650, 2013
PubMed
4) Tatsuno K, et al : Emergence of Photosensitivity with Decreased Treg Cells in a Patient with Mycosis Fungoides Treated with Anti-CC Chemokine Receptor 4 Antibody Mogamulizumab. Acta Derm Venereol 96 : 420-421, 2016
 
5) Masuda Y, et al : Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms. J Eur Acad Dermatol Venereol 32 : 1456-1460, 2018
PubMed
P.56 掲載の参考文献
1) 大槻マミ太郎 : 生物学的製剤の使い方. 皮病診療 33 (増) : 144-149 , 2011
 
2) Checkley LA, et al : Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting. Dig Dis Sci 64 : 855-862, 2019
 
3) Wang J, et al : A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. Hum Vaccin Immunother 12 : 431-7, 2016
 
4) Choquette D, et al : Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry. J Rheumatol 42 : 1105-1111, 2015
 
5) Lichtenstein L, et al : Infliximab-Related Infusion Reactions : Systematic Review. J Crohns Colitis 9 : 806-815, 2015
PubMed
6) 日本皮膚科学会乾癬生物学的製剤検討委員会 (委員長 : 大槻マミ太郎) : 乾癬における生物学的製剤の使用ガイダンス (2018年版). 日本皮膚科学会ホームページ
 
7) Fumery M, et al : Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases : A systematic review and meta-analysis. Dig Liver Dis 51 : 484-488, 2019
PubMed
8) Okuyama A, et al : Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70 : 299-304, 2011
 
P.60 掲載の参考文献
1) 山口由衣 : TNF-α阻害薬による逆説的反応-乾癬様・掌蹠膿疱症様皮疹-. アレルギーの臨床 37 : 445-449, 2017
 
2) 朝比奈昭彦 : Biologicsによる薬疹. 臨皮 63 : 9-13, 2009
 
3) 尾本百香, ほか : アダリムマブによる治療中に乾癬性関節炎から汎発性膿疱性乾癬へ移行した1例. 皮膚臨床 61 : 597-601, 2019
 
4) Mylonas A, Conrad C : Psoriasis : Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol 9 : 2746, 2018
PubMed
5) 唐川大, ほか : 生物学的製剤による皮膚障害-乾癬様皮疹を含めて. 臨皮 65 : 10-14, 2011
 
6) Collamer AN, et al : Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Arthritis Rheum 59 : 996-1001, 2008
PubMed
7) Conrad C, et al : TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 9 : 25, 2018
PubMed
8) Garcovich S, et al : Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. Front Pharmacol 10 : 282, 2019
PubMed
9) Seneschal J, et al : Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions asso ciated w ith ant itumour necrosis factor-alpha treatments. Br J Dermatol 161 : 1081-1088, 2009
 
10) Nestle FO, et al : Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202 : 135-143, 2005
PubMed
11) de Gannes GC, et al : Psoriasis and pustular dermatitis triggered by TNF-｛alpha｝ inhibitors in patients with rheumatologic conditions. Arch Dermatol 143 : 223-231, 2007
PubMed
P.65 掲載の参考文献
1) Al-Khalili A, Dutz JP : Immunosuppression/Infections across Indications. Curr Probl Dermatol 53 : 28-36, 2018
PubMed
2) Pol A, Pfundt R, et al : Transcriptional regulation of the elafin gene in human keratinocytes. J Invest Dermatol 120 : 301-307, 2003
PubMed
3) Zeeuwen PL, et al : Genetically programmed differences in epidermal host defense between psoriasis and atopic dermatitis patients. PLoS One 3 : e2301, 2008
PubMed
4) Fahlen A, et al : Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res 304 : 15-22, 2012
PubMed
5) Kolbinger F, et al : β-defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol 139 : 923-932, 2017
 
6) 角木基彦, 岩倉洋一郎 : IL-17と感染防御. 臨免疫・アレルギー科 57 : 430-436, 2012
 
7) Ye P, et al : Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194 : 519-527, 2001
PubMed
8) Lin Y, et al : Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31 : 799-810, 2009
 
9) Ishigame H, et al : Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30 : 108-119, 2009
PubMed
10) Saijo S, et al : Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 32 : 681-691, 2010
PubMed
11) Dejima T, et al : Protective role of naturally occurring interleukin-17A-producing γδ T cells in the lung at the early stage of systemic candidiasis in mice. Infect Immun 79 : 4503-4510, 2011
 
12) Conti HR, et al : Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206 : 299-311, 2009
PubMed
13) Minegishi Y, et al : Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 : 1058-1062, 2007
PubMed
14) Zelante T, et al : IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37 : 2695-2706, 2007
PubMed
15) Wu KK, et al : Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. J Dermatolog Treat 22 : 1-7, 2019
 
16) Blauvelt A : Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf 15 : 1413-1420, 2016
PubMed
17) DM Saunte, et al : Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 177 : 47-62, 2017
 
18) Davila-Seijo P, et al : Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs : Findings from the BIOBADADERM Registry. J Invest Dermatol 137 : 313-321, 2017
PubMed
19) Kalb RE, et al : Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis : Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol 151 : 961-969, 2015
PubMed
20) Tsiodras S, et al : Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83 : 181-194, 2008
PubMed
21) Salt E, et al : Risk Factors for Targeted Fungal and Mycobacterial Infections in Patients Taking Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol 68 : 597-603, 2016
PubMed
P.71 掲載の参考文献
1) 伊藤泰介 : 円形脱毛症. 皮膚免疫アレルギーハンドブック, 戸倉新樹ほか (編), 南江堂, p301-309, 2018
 
2) Ito T, Tokura Y : Alopecia areata triggered or exacerbated by swine flu virus infection. J Dermatol 39 : 863-864, 2012
 
3) Abou Rahal J, et al : Plasmacytoid dendritic cells in alopecia areata : missing link? J Eur Acad Dermatol Venereol 30 : 119-123, 2016
 
4) Saadeh D, et al : Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol 25 : 415-421, 2016
PubMed
5) Ghoreishi M, et al : Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol 163 : 57-62, 2010
PubMed
6) Ito T, et al : Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege. Eur J Dermatol 24 : 631-633, 2014
 
7) Ettefagh L, et al : Alopecia areata in a patient using infliximab : new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 140 : 1012, 2004
 
8) Posten W, Swan J : Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 141 : 759-760, 2005
 
9) Garcia Bartels N, et al : Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 142 : 1654-1655, 2006
 
10) Tauber M, et al : Alopecia areata occurring during anti-TNF therapy : a national multicenter prospective study. J Am Acad Dermatol 70 : 1146-1149, 2014
PubMed
11) Palucka AK, et al : Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102 : 3372-3377, 2005
PubMed
12) Cantaert T, et al : Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease : basic concepts and clinical relevance. Arthritis Res Ther 12 : 219, 2010
 
13) Tojo G, et al : Comparison of interleukin-17- producing cells in different clinical types of alopecia areata. Dermatology 227 : 78-82, 2013
PubMed
14) Tanemura A, et al : Alopecia areata : infiltration of Th17 cells in the dermis, particularly around hair follicles. Dermatology 226 : 333-336, 2013
PubMed
15) El-Morsy EH, et al : Serum level of interleukin-17A in patients with alopecia areata and its relationship to age. Int J Dermatol 55 : 869-874, 2016
PubMed
16) Loh SH, et al : Role of T helper 17 cells and T regulatory cells in alopecia areata : comparison of lesion and serum cytokine between controls and patients. J Eur Acad Dermatol Venereol 32 : 1028-1033, 2018
 
17) Guttman-Yassky E, et al : Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res 310 : 607-614, 2018
PubMed
18) Topalian SL, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443-2454, 2012
PubMed
19) Hofmann L, et al : Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 : 190-209, 2016
PubMed
20) Zarbo A, et al : Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 176 : 1649-1652, 2017
PubMed
21) Guleria I, et al : A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 202 : 231-237, 2005
PubMed
22) Cheng X, et al : Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege. Transplantation 87 : 1778-1786, 2009
PubMed
23) Hori J, et al : B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 177 : 5928-5935, 2006
PubMed
24) Jaber SH, et al : Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 142 : 166-172, 2006
 
25) Assi H, Wilson KS : Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma : two illustrative cases. Curr Oncol 20 : e165-e169, 2013
PubMed
P.73 掲載の参考文献
1) Baker H, Ryan TJ : Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 80 : 771-793, 1968
PubMed
2) Roujeau JC, et al : Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 127 : 1333-1338, 1991
PubMed
3) Sidoroff A, et al : Acute generalized exanthematous pustulosis (AGEP) --a clinical reaction pattern. J Cutan Pathol 28 : 113-119, 2001
PubMed
4) Katz M, et al : Penicillin-induced generalized pustular psoriasis. J Am Acad Dermatol 17 : 918-920, 1987
PubMed
5) Sugiura K, et al : The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 133 : 2514-2521, 2013
PubMed
6) Sugiura K, et al : CARD14 c.526G > C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol 134 : 1755-1757, 2014
 
7) Sugiura K, et al : Generalized pustular psoriasis triggered by amoxicillin in monozygotic twins with compound heterozygous IL36RN mutations : comment on the article by Navarini et al. J Invest Dermatol 134 : 578-579, 2014
 
8) Nakai N, et al : Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol 151 : 311-315, 2015
 
9) Podlipnik S, et al : Acute generalized exanthematous pustulosis and polyarthritis associated with a novel CARD14 mutation. Australas J Dermatol 59 : e70-e73, 2018
PubMed
P.75 掲載の参考文献
1) Thyssen JP, et al : Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol 77 : 280-286, 2017
PubMed
2) Akinlade B, et al : Conjunctivitis in dupilumab clinical trials. Br J Dermatol 181 : 459-473, 2019
PubMed
3) Thyssen JP : Could conjunctivitis in patients with atopic dermat it is treated w ith dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 178 : 1220, 2018
 
4) Bakker DS, et al : Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180 : 1248-1249, 2019
PubMed
5) Treister AD, et al : Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatol 154 : 1208-1211, 2018
PubMed
6) Wollenberg A, et al : Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6 : 1778-1780, 2018
PubMed
7) Ivert LU, et al : Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis. Acta Derm Venereol 99 : 375-378, 2019
PubMed
P.80 掲載の参考文献
1) Nishie W : Update on the pathogenesis of bullous pemphigoid : an autoantibody-mediated blistering disease targeting collagen XVII. J Dermatol Sci 73 : 179-186, 2014
PubMed
2) Forsti AK, et al : Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26 : 1228-1234, 2017
PubMed
3) Attaway A, et al : Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 8 : 24-28, 2014
PubMed
4) Yazbeck R, et al : Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 30 : 600-607, 2009
PubMed
5) Benzaquen M, et al : Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid : Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 78 : 1090-1096, 2018
PubMed
6) Murrell DF, et al : Definitions and outcome measures for mucous membrane pemphigoid : recommendations of an international panel of experts. J Am Acad Dermatol 72 : 168-174, 2015
PubMed
7) Horikawa H, et al : Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol 178 : 1462-1463, 2018
PubMed
8) Izumi K, et al : Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. J Invest Dermatol 136 : 2201-2210, 2016
PubMed
9) Kobayashi M, et al : BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 30 : 224-232, 2002
PubMed
10) Mai Y, et al : Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid : a report of three patients. Br J Dermatol 179 : 790-791, 2018
PubMed
11) Takama H, et al : Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid : Recurrence with Epitope Spreading. Acta Derm Venereol 98 : 983-984, 2018
PubMed
12) 西江渉 : DPP-4阻害薬関連水疱性類天疱瘡. 西日皮 78 : 583-588, 2016
 
13) Bene J, et al : Bullous pemphigoid and dipeptidyl peptidase IV inhibitors : a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol 175 : 296-301, 2016
PubMed
14) Kridin K, Bergman R : Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes : Estimating the Risk of the New Agents And Characterizing the Patients. JAMA Dermatol 154 : 1152-1158, 2018
 
15) Plaquevent M, et al : Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. J Invest Dermatol 139 : 835-841, 2019
PubMed
16) Lee SG, et al : Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. JAMA Dermatol 155 : 172-177, 2019
PubMed
17) Arai M, et al : Bullous Pemphigoid and Dipeptidyl Peptidase 4 inhibitors : A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care 41 : e130-e132, 2018
PubMed
18) 木村徹子, ほか : DPP-4 (dipeptidyl peptidase-4) 阻害薬内服後に発症した水疱性類天疱瘡患者の臨床病型の検討. 日皮会誌 128 : 2645-2651 , 2018
 
19) Okauchi Y, et al : Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor : A case report. J Dermatol 45 : e39-e40, 2018
PubMed
20) Ujiie H, et al : HLA-DQB1*03 : 01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol 138 : 1201-1204, 2018
PubMed
P.87 掲載の参考文献
1) 福田英三, 福田英嗣 : 薬疹情報 第17版 (1980-2016). 福田皮ふ科クリニック, 2017
 
2) 百瀬葉子, ほか : 煎剤中の黄耆による扁平苔癬型薬疹. 日皮アレルギー会誌 12 : 30-34, 2004
Medical*Online
3) 金指麦子, ほか : Cinnamic Aldehyde含有漢方薬による薬疹の4症例. 皮膚臨床 37 : 715-719, 1995
 
4) 久保田智樹, ほか : 葛根湯中のマオウによる播種状紅斑丘疹型薬疹の1例. 日皮アレルギー会誌 12 : 9-13, 2004
Medical*Online
5) 清水秀樹, ほか : 総合感冒薬および麻黄の成分である塩酸プソイドエフェドリンによる急性汎発性発疹性膿疱症. 日皮会誌 115 : 2245-2249, 2005
 
6) 内藤裕史 : 腸間膜静脈硬化症と漢方生薬・山梔子との関係. 日医会誌 142 : 585-591, 2013
 
7) 金澤伸雄, ほか : 漢方薬内服により誘発されたショウガアレルギー. J Environ Dermatol Cutan Allergol 9 : 424, 2015
Medical*Online
8) Lim YL, Thirumoorthy T : Serious cutaneous adverse reactions to traditional Chinese medicines. Singapore Med J 46 : 714-717, 2005
PubMed
9) 永尾圭介 : 薬疹の検査法-薬剤添加リンパ球刺激試験 (DLST) の原理と読み方-. Derma 198 : 29-34, 2012
Medical*Online
10) 西村明子, ほか : 健常人における漢方薬によるリンパ球刺激試験に関する検討. 皮の科 9 : 452-457, 2010
 
11) Norisugi O, et al : In vitro cytokine expression by peripheral mononuclear cells in herbal drug-induced skin eruption. Acta Derm Venereol 94 : 58-62, 2014
PubMed
12) 花田豪郎, ほか : 好塩基球活性化試験が原因薬剤の同定に有用であった葛根湯による薬剤性肺障害の1例. 日呼吸誌 1 : 135-140, 2012
 
P.93 掲載の参考文献
1) 千貫祐子, ほか : セツキシマブによるアナフィラキシーショックの4例-α-gal特異的IgE検出による回避の可能性-. 日皮会誌 124 : 179-183, 2014
 
2) Yamaguchi K, et al : Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer : results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan. Jpn J Clin Oncol 44 : 541-546, 2014
 
3) Chung CH, et al : Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 : 1109-1117, 2008
PubMed
4) Commins SP, et al : Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 123 : 426-433, 2009
 
5) Commins SP, et al : The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol 127 : 1286-1293, 2011
 
6) 千貫祐子, ほか : 牛肉アレルギー患者20例の臨床的および血清学的解析. 日皮会誌 123 : 1807-1814, 2013
 
7) Chinuki Y, et al : Haemaphysalis longicornis tick bites are a possible cause of red meat allergy in Japan. Allergy 71 : 421-425, 2016
PubMed
8) 千貫祐子 : セツキシマブによるアナフィラキシー. Derma 264 : 69-75, 2017
Medical*Online
9) Hashizume H, et al : Repeated Amblyomma testudinarium tick bites are associated with increased galactose-α-1,3-galactose carbohydrate IgE antibody levels : A retrospective cohort study in a single institution. J Am Acad Dermatol 78 : 1135-1141, 2018
 
10) Wada T, et al : Selective ablation of basophils in mice reveals their nonredundant role in acquired immunity against ticks. J Clin Invest 120 : 2867-2875, 2010
PubMed
11) Chinuki Y, et al : Alpha-Gal-containing biologics and anaphylaxis. Allergol Int 68 : 296-300, 2019
PubMed
P.98 掲載の参考文献
1) James JA, et al : Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16 : 401-409, 2007
PubMed
2) Canadian Hyderoxychloroquine Study Group : A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324 : 150-154, 1991
 
3) Alarcon GS, et al : Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus : data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66 : 1168-1172, 2007
 
4) Fava A, Patri M : Systemic lupus erythematosus : Diagnosis and clinical management. J Autoimmun 96 : 1-13, 2019
 
5) Wallace DJ : Antimalarial drugs in the treatment of rheumatic diseases. In : Furst DE, editor. Wellesley MA : UpToDate : 2017.
 
6) Tett SE, et al : Bioavailability of hyderoxychloroquine tablets n healthy volunteers. Br J Clin Pharmacol 27 : 771-779, 1989
 
7) Frust DE : Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheuatic diseases. Lupus 5 (suppl 1) : S11-15, 1996
 
8) Mates M, et al : Desensitization to hydroxychloroquine--experience of 4 patients. J Rheumatol 33 : 814-816, 2006
PubMed
9) Leckie MJ, Rees RG : Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. Rheumatology (Oxford) 41 : 473-474, 2002
PubMed
10) Paradisi A, et al : Acute generalized exanthematous pustulosis induced by hydroxychloroquine : three cases and a review of the literature. Clin Ther 30 : 930-940, 2008
 
11) Volpe A, et al : Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol 27 : 537-539, 2008
PubMed
12) Cameron MC, et al : Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J 20 : pii 13030/qt1q90q0h5, 2014
 
13) Duman H, et al : Acute generalized exanthematous pustulosis induced by hydroxychloroquine : a case with atypical clinical presentation. An Bras Dermatol 92 : 404-406, 2017
PubMed
14) Girijala RL, et al : Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation. J Drugs Dermatol 18 : 207-209, 2019
PubMed
15) Murphy M, Carmichael AJ : Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 26 : 457-458, 2001
PubMed
16) Garcovich S, et al : Paradoxycal Skin Reaction to Biologics in Patients With Rheumatologic Disorders. Front Pharmacol 10 : 282, 2019
 
17) 佐野栄紀 : 生物学的製剤のパラドックス反応機序. 臨皮 69 (増) : 59-62, 2015
 
18) McCoy SS, et al : Exacerbation of Psoriasis due to hydroxychloroquine. ARCHIVES OF MEDICINE 7 : 9, 2015
 
19) Wang WM, et al : Hydroxychloroquine-Indaced Psoriasisform Erythroderma in a Patient with Systemic Lupus Erythematosus. Chin Med J (Engl) 131 : 1887-1888, 2018
 
20) Riley K, et al : Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatol 155 ; 491-493, 2019
PubMed
21) Gonzalez CD, et al : Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis : A retrospective cohort study. J Am Acad Dermatol 81 : 859-860, 2019
PubMed
22) Soria A, et al : Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests. Dermatology 231 : 353-359, 2015
PubMed
23) Matsuda T, et al : Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient : A case report and review of the published work. J Dermatol 45 : 344-348, 2018
 
24) Coulombe J, Boccara O : Hydroxychloroquine-related skin discoloration. CMAJ 189 : E212, 2017
PubMed
P.102 掲載の参考文献
1) Nazarian RM, et al : Warfarin-induced skin necrosis. J Am Acad Dermatol 61 : 325-332, 2009
PubMed
2) Klein L, et al : Warfarin-induced limb gangrene in the setting of lung adenocarcinoma. Am J Hematol 76 : 176-179, 2004
PubMed
3) Hamada T, et al : Warfarin-induced skin necrosis accompanied by aggravation of vasculitis in a patient with cutaneous arteritis. Int J Dermatol 56 : 779-781, 2017
 
4) 長谷川元 : 透析患者に対するワーファリン使用に関する諸問題 有効性と危険性, Calciphylaxis , ワーファリン皮膚壊死, ワーファリン関連腎症. 日血管外会誌 26 : 83-90, 2017
Medical*Online
5) 中村考伸, ほか : Calciphylaxis によると考えられた陰茎壊死の1例. Skin Surg 19 : 98-102, 2010
Medical*Online
6) 林松彦, ほか : 全国調査に基づくカルシフィラキシス診断基準の提案. 日透析医学会誌 45 : 551-557, 2012
 
7) 渡邉萌理, ほか : Deep dissecting hematomaの1例. 皮膚臨床 56 : 683-686 , 2014
 
P.104 掲載の参考文献
1) Nelson CA, et al : Neutrophilic dermatoses : Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behcet disease. J Am Acad Dermatol 79 : 987-1006, 2018
PubMed
2) Filosa A, Filosa G : Neutrophilic dermatoses : a broad spectrum of disease. G Ital Dermatol Venereol 153 : 265-272, 2018
PubMed
3) Nelson CA, et al : Sweet syndrome in patients with and without malignancy : A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol 78 : 303-309, 2018
 
4) Giasuddin AS, et al : Sweet's syndrome : is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 39 : 940-943, 1998
PubMed
5) von den Driesch P : Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 31 : 535-556, 1994
PubMed
6) Walker DC, Cohen PR : Trimethoprim-sulfamethoxazoleassociated acute febrile neutrophilic dermatosis : case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 34 : 918-923, 1996
 
7) Nofal A, et al : Sweet's syndrome : diagnostic criteria revisited. J Dtsch Dermatol Ges 15 : 1081-1088, 2017
PubMed

第II章 薬剤による特殊な皮膚障害

P.111 掲載の参考文献
1) Ozaki C, et al : Case of photosensitivity after the administration of olmesartan medoxomil. J Dermatol 45 : e277-e278, 2018
PubMed
2) Masuoka E, et al : Dysfunction of melanocytes in photoleukomelanoderma following photosensitivity caused by hydrochlorothiazide. Photodermatol Photoimmunol Photomed 27 : 328-330, 2011
PubMed
3) Kunisada M, et al : Hydrochlorothiazide enhances UVA-induced DNA damage. Photochem Photobiol 89 : 649-654, 2013
PubMed
4) Pedersen SA, et al : Hydrochlorothiazide use and risk of nonmelanoma skin cancer : A nationwide case-control study from Denmark. J Am Acad Dermatol 78 : 673-681, 2018
 
5) Luu M, et al : Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 23 : 42-45, 2007
 
6) Fukai T, et al : Case of erlotinib-induced photosensitivity. J Dermatol 41 : 445-446, 2014
PubMed
7) Papakonstantinou E, et al : Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis. J Eur Acad Dermatol Venereol 30 : 1354-1356, 2016
 
8) Goyal RK : Voriconazol-associated phototoxic dermatoses and skin cancer. Expert Rev Anti Infect Ther 13 : 1537-1546, 2015
PubMed
9) Ikeya S, et al : Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation. Sci Rep 22 : 5050, 2018
 
10) Kuwatsuka S, et al : Case of photosensitivity caused by fenofibrate after photosensitization to ketoprofen. J Dermatol 43 : 224-225, 2016
PubMed
11) Hong JH, et al : Fenofi brate-Induced Photosensitivity-A Case Report and Literature Review. Dermatol Sinica 27 : 37-43, 2009
 
P.117 掲載の参考文献
1) Herbrecht R, et al : Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 : 408-415, 2002
PubMed
2) Johnson LB, Kauffman CA : Voriconazole : a new triazole antifungal agent. Clin Infect Dis 36 : 630-637, 2003
PubMed
3) Ratushny V, et al : From keratinocyte to cancer : the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122 : 464-472, 2012
PubMed
4) Williams K, et al : Voriconazole-associated cutaneous malignancy : a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 58 : 997-1002, 2014
PubMed
5) McCarthy KL, et al : Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 44 : e55-56, 2007
PubMed
6) Cowen EW, et al : Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 62 : 31-37, 2010
PubMed
7) Tang H, et al : Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients : A systematic review and meta-analysis. J Am Acad Dermatol 80 : 500-507, 2019
PubMed
8) Hyland R, et al : Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31 : 540-547, 2003
 
9) Ona K, Oh DH : Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A. Br J Dermatol 173 : 751-759, 2015
 
10) Ikeya S, et al : Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation. Sci Rep 8 : 5050, 2018
PubMed
11) 戸倉新樹 : 光線過敏型薬疹. 最新皮膚科学体系 第5巻 (1版), 玉置邦彦編. 中山書店, P75-82, 2004
 
12) Fukushima A, et al : A Case of Cutaneous Squamous Cell Carcinoma Suspected to Be Induced by Voriconazole Phototoxicity. Jpn J Dermatol 126 : 411-418, 2016
 
13) Tone J, et al : Two Cases of Rapidly Progressive Squamous Cell Carcinomas Emerging during Long-term Voriconazole Therapy. J Environ Dermatol Cutan Allergol 10 : 29-34, 2016
Medical*Online
14) Epaulard O, et al : A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma : results from a French nationwide study. Clin Infect Dis 57 : e182-188, 2013
PubMed
15) Murayama N, et al : Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 73 : 2020-2026, 2007
 
16) Stockinger B, et al : The aryl hydrocarbon receptor : multitasking in the immune system. Annu Rev Immunol 32 : 403-432, 2014
PubMed
17) Tsuji G, et al : Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes : the basis of its anti-inflammatory effect. J Invest Dermatol 132 : 59-68, 2012
PubMed
18) van den Bogaard EH, et al : Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 123 : 917-927, 2013
PubMed
P.122 掲載の参考文献
1) Quattrone F, et al : Cutaneous ulcers associated with hydroxyurea therapy. J Tissue Viability 22 : 112-121, 2013
PubMed
2) 本間大, 飯塚一 : ヒドロキシカルバミド (ハイドレア(R)) による皮膚潰瘍. 皮膚臨床 54 (臨増) : 1583-1587, 2012
 
3) 畠清彦 (監) : ハイドレア(R) カプセルを服用される患者さまへ. ブリストル・マイヤーズ スクイブ, 2016 (https://www.bms.com/assets/bms/japan/documents/11-27-17/HDpatient1607.pdf)
 
4) Simeonovski V, et al : Hydroxyurea Associated Cutaneous Lesions : A Case Report. Open Access Maced J Med Sci 6 : 1458-1461, 2018
PubMed
5) 村田朋子, ほか : ハイドロキシウレアによる難治性の皮膚潰瘍部に生じた有棘細胞癌の1例. 臨皮 63 : 249-252, 2009
 
6) 石川由華, ほか : ハイドレア内服中に顔面に多発した有棘細胞癌. 皮病診療 27 : 1281-1284, 2005
 
7) Ito E, et al : Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema. Dermatol Online J 20 : pii : 13030/qt2r11f768, 2014
 
8) Agrawal PG, et al : Gottron-like papules induced by hydroxyurea. Indian J Dermatol Venereol Leprol 78 : 775, 2012
PubMed
9) 岩間英明, ほか : 分層植皮術を施行したヒドロキシカルバミドによる下腿潰瘍の1例. 皮膚臨床 58 : 376-379, 2016
 
10) 井上雄二, ほか : 創傷・熱傷ガイドライン委員会報告-1 : 創傷一般. 日皮会誌 121 : 1539-1559, 2011
 
11) 臼井圭子, ほか : ハイドロキシウレアを18年間内服後に生じた下腿潰瘍. 皮膚臨床 50 : 609-612, 2008
 
12) 東前和奈, ほか : ハイドロキシウレアによる皮膚潰瘍 : 薬剤中止後にも症状が再燃した1例. 皮の科 12 : 74-78, 2013
 
13) 矢野有沙, ほか : ハイドロキシウレアの投与中に生じた難治性皮膚潰瘍部に有棘細胞癌およびボーエン病を合併した1例. Skin Cancer 32 : 39-43, 2017
 
14) Antar A, et al : Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematol Oncol Stem Cell Ther 7 : 166-169, 2014
PubMed
15) Salmon-Ehr V, et al : Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment. Dermatology 196 : 274, 1998
PubMed
16) Koch L, et al : Dermatitis, nonmelanoma skin cancer and leg ulcers. Clin Exp Dermatol 41 : 943-944, 2016
PubMed
P.130 掲載の参考文献
1) Haustein UF, Haupt B : Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol 16 : 353-366, 1998
PubMed
2) Palestine RF, et al : Skin manifestations of pentazocine abuse. J Am Acad Dermatol 2 : 47-55, 1980
PubMed
3) Bogdan C, Ding A : Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52 : 119-121, 1992
PubMed
4) Tsavaris N, et al : Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87 : 21-27, 2002
PubMed
5) Clark JG, et al : Bleomycin-induced synthesis of type I procollagen by human lung and skin fibroblasts in culture. Biochim Biophys Acta 631 : 359-370, 1980
PubMed
6) Motegi S, et al : Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. Exp Dermatol 23 : 664-669, 2014
PubMed
7) Okada K, et al : Glycosaminoglycan and versican deposits in taxane-induced sclerosis. Br J Dermatol 173 : 1054-1058, 2015
PubMed
8) Battafarano DF, et al : Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 76 : 110-115, 1995
PubMed
9) Extra JM, et al : Phase I and pharmacokinetic study of Taxotere (RP 56976 ; NSC 628503) given as a short intravenous infusion. Cancer Res 53 : 1037-1042, 1993
 
10) Farrant PB, et al : Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol 29 : 360-362, 2004
PubMed
11) Itoh M, et al : Taxane-induced scleroderma. Br J Dermatol 156 : 363-367, 2007
PubMed
12) Alexandrescu DT, et al : Chemotherapy-induced scleroderma : a pleiomorphic syndrome. Clin Exp Dermatol 30 : 141-145, 2005
PubMed
13) Winkelmann RR, et al : Paclitaxel-induced diffuse cutaneous sclerosis : a case with associated esophageal dysmotility, Raynaud' s phenomenon, and myositis. Int J Dermatol 55 : 97-100, 2016
PubMed
14) Bessis D, et al : Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 51 (2 Suppl) : S73-S76, 2004
 
15) Chu CY, et al : Gemcitabine-induced acute lipodermatosclerosis-like reaction. Acta Derm Venereol 81 : 426-428, 2001
PubMed
16) Verhulst L, et al : Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature. Int J Dermatol 57 : 1075-1079, 2018
 
17) NSFとガドリニウム造影剤使用に関する合同委員会 : 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン 第2版. 2009 (https://cdn.jsn.or.jp/jsn_new/news/guideline_nsf_090902.pdf)
 
18) Ishikawa K, et al : Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma. J Dermatol 43 : 1071-1074, 2016
PubMed
19) Peroni A, et al : Drug-induced morphea : report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 59 : 125-129, 2008
PubMed
20) Andreussi R, et al : Systemic sclerosis induced by the use of cocaine : is there an association? Rheumatol Int 39 : 387-393, 2019
PubMed
P.135 掲載の参考文献
1) 竹石美智雄, 三村俊英 : ロイコボリンおよびクエストランによるレスキュー. リウマチ科 32 : 178-184, 2004
 
2) 糟谷啓, ほか : メトトレキサート投与中の関節リウマチ患者の下腿に出現したB細胞リンパ腫の1例. 臨皮 64 : 319-322, 2010
 
3) 糟谷啓 : 免疫抑制剤とリンパ増殖性疾患. 皮アレルギーフロンテ 8 : 81-84, 2010
Medical*Online
4) 糟谷啓, ほか : 免疫抑制剤とリンパ腫. 日皮会誌 126 : 1433-1438, 2016
 
5) Hatano T, et al : Methotrexate-Related Lymphoproliferative Disorder Presenting with Severe Swelling of the Elbow Joint : A Case Report. JBJS Case Connect 7 : e65, 2017
PubMed
6) Abe A, et al : A case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee. Mod Rheumatol 28 : 550-554, 2018
 
7) Furukawa S, et al : Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw : A Case Report and Literature Review . Intern Med 57 : 575-581, 2018
PubMed
8) 青田泰雄, ほか : 腸管穿孔を契機に診断に至ったメトトレキサート関連リンパ増殖性疾患 (methotrexate-associated lymphoproliferative disorder : MTX-LPD). 日老医誌 54 : 567-572, 2017
 
9) Tokuyama K, et al : EBV-positive MTX-diffuse large B cell lymphoma in a rheumatoid arthritis patient. Jpn J Radiol 32 : 183-187, 2014
 
10) Kobayashi Y, et al : Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis : a case report . Jpn J Ophthalmol 60 : 212-218, 2016
 
11) Horie N, et al : Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis . Aust Dent J 60 : 408-411, 2015
PubMed
12) Mariette X, et al : Lymphomas in rheumatoid arthritis patients treated with methotrexate : a 3-year prospective study in France. Blood 99 : 3909-3915, 2002
PubMed
13) Aiko N, et al : The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis : A Case Report and Literature Review. Intern Med 57 : 3163-3167, 2018
PubMed
14) Cornejo CM, et al : Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate . Cutis 98 : 253-256, 2016
PubMed
15) Niitsu N, et al : Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 101 : 1309-1313, 2010
PubMed
16) Rizzi R, et al : Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26 : 1-9, 2009
PubMed
17) Sato A, et al : Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era . Cancer Sci 105 : 1170-1175, 2014
PubMed
18) Okamoto A, et al : The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. Hematol Oncol 35 : 87-93, 2017
PubMed
19) Katsuyama T, et al : Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol 27 : 773-777, 2017
PubMed
20) Gao X, et al : Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma : A meta-analysis. PLoS One 13 : e0199398, 2018
PubMed
21) Raaby L, et al : Methotrexate Use and Monitoring in Patients with Psoriasis : A Consensus Report Based on a Danish Expert Meeting. Acta Derm Venereol 97 : 426-432, 2017
PubMed
22) Suzuki M, et al : Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology 12 : 774-776, 2007
PubMed
23) Paul C, et al : Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 133 : 867-871, 1997
PubMed
24) Zintzaras E, et al : The risk of lymphoma development in autoimmune diseases : a meta-analysis. Arch Intern Med 165 : 2337-2344, 2005
PubMed
25) Gelfand JM, et al : The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 : 2194-2201, 2006
PubMed
P.138 掲載の参考文献
1) Imbach P, et al : High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 : 1228-1231, 1981
PubMed
2) Brannagan TH 3rd, et al : Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47 : 674-677, 1996
PubMed
3) Barbaud A, et al : A baboon syndrome induced by intravenous human immunoglobulins : report of a case and immunological analysis. Dermatology 199 : 258-260, 1999
PubMed
4) 市川博雄, ほか : 免疫性神経疾患に対する免疫グロブリン静注療法の副作用に関する研究. 神経治療 19 : 607-614, 2002
Medical*Online
5) 他田正義, ほか : 大量免疫グロブリン静注療法 (IVIG) による汗疱様皮膚障害. 脳と神経 55 : 401-405, 2003
 
6) Whittam LR, et al : Eczematous reactions to human immune globulin. Br J Dermatol 137 : 481-482, 1997
PubMed
7) 横山恵美, ほか : 特発性血小板減少性紫斑病患者に免疫グロブリンを大量投与後に生じた汗疱の1例. 皮膚臨床 46 : 1246-1247, 2004
 
8) 田口佳代子, ほか : 免疫グロブリン大量療法にて生じた汗疱の4例. 皮膚臨床 49 : 1073-1076 , 2007
 
9) 定平知江子, ほか : 免疫グロブリン大量療法後に汗疱からはじまる皮膚障害を呈した2例. J Environ Dermatol Cutan Allergol 4 : 154-162, 2010
Medical*Online
10) Gurcan HM , Ahmed AR : Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid, Ann Pharmacother 41 : 1604-1610, 2007
PubMed
11) Maetzke J, et al : Vesicular and bullous eczema in response to intravenous immunoglobulins (IVIG). Allergy 61 : 145-146, 2006
PubMed
12) Rhee DY, et al : Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barre syndrome. J Eur Acad Dermatol Venereol 23 : 602-604, 2009
PubMed
13) 鈴木敬子, ほか : γグロブリン大量療法により汗疱様皮疹を生じた1例. 皮の科 4 : 31-35, 2005
 
14) Paquet P, et al : Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 15 : 381-386, 2006
PubMed
P.143 掲載の参考文献
1) 平成28年国民健康・栄養調査結果の概要 : 厚生労働省健康局健康課栄養指導室栄養調査課係 : (https://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/kekkagaiyou_7.pdf)
 
2) Nagase T, et al : The insulin ball. Lancet 373 : 184, 2009
PubMed
3) McNally PG, et al : Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J 64 : 850-853, 1988
PubMed
4) Storkel S, et al : Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest 48 : 108-111, 1983
PubMed
5) Dische FE, et al : Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 31 : 158-161, 1988
 
6) 伊藤志保, ほか : Insulin-induced lipohypertrophyの1例. 臨皮 51 : 1020-1022, 1997
 
7) Young RJ, et al : Insulin Injection sitesin diabetes--a neglected area? Br Med J 283 : 349, 1981
 
8) 吉嵜友之, 本田宗宏 : インスリン吸収に及ぼす影響を検討しえた皮下局所的アミロイド沈着の1例. 糖尿病 55 : 786-792, 2012
 
9) 田嶼尚子, ほか : 1型糖尿病の実態調査, 客観的診断基準, 日常生活・社会生活に着目した重症度評価の作成に関する研究. 平成28年度厚生労働科学研究成果データベース (https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201608013A)
 
10) 末木博彦 : アミロイドーシス診療のアルゴリズム. 皮膚臨床 55 : 167-175, 2013
 
11) Shikama Y, et al : Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med 49 : 397-401, 2010
 
12) 楠和久, ほか : インスリン注射による皮下腫瘤の病理組織, 画像所見およびインスリン吸収についての検討. 糖尿病 58 : 388-397, 2015
 
13) 高尾真理子, ほか : インスリン注射部位に生じた限局性皮膚アミロイドーシスの1例. 皮膚臨床 54 : 796-797, 2012
 
14) 大谷稔男 : インスリンボール. 臨皮 67 : 18-22, 2013
 
P.145 掲載の参考文献
1) 福田英三, 福田英嗣 : 薬疹情報 (第17版). 福田皮ふ科クリニック, 2017
 
2) 檜垣祐子 : 苔癬型薬疹. 薬疹のすべて, 池澤善郎, 相原道子編, 南江堂, p213, 2008
 
3) 福田英嗣 : 苔癬型薬疹 今と昔. 皮膚病診療 32 : 563-569, 2010
 
4) 小玉肇 : 苔癬型薬疹と扁平苔癬. 皮膚科診療プラクティス 19 薬疹を極める, 塩原哲夫ほか編, 文光堂, p165-168, 2006
 
5) 川島啓道, ほか : ニボルマブによる扁平苔癬型薬疹の1例. 皮膚臨床 61 : 17-21, 2019
 
6) Freeman-Keller M, et al : Nivolumab in Resected and Unresectable Metastatic Melanoma : Characteristics of Immune-Related Adverse Events and Association with Outcomes . Clin Cancer Res 22 : 886-894, 2016
PubMed
7) 塩原哲夫 : Lichen PlanusとLichenoid Drug Eruption . 皮膚臨床 38 : 1207-1211, 1996
 

第III章 有害事象の発生機序

P.152 掲載の参考文献
1) Schon MP, Schon M : TLR7 and TLR8 as targets in cancer therapy. Oncogene 27 : 190-199, 2008
PubMed
2) Drobits B, et al : Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122 : 575-585, 2012
 
3) Yokogawa M, et al : Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells. Mol Carcinog 52 : 760-769, 2013
PubMed
4) Gilliet M, et al : Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 140 : 1490-1495, 2004
PubMed
5) Patel U, et al : Imiquimod 5% cream induced psoriasis : a case report, summary of the literature and mechanism. Br J Dermatol 164 : 670-672, 2011
PubMed
6) van der Fits L, et al : Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182 : 5836-5845, 2009
 
7) Kataoka S, et al : Distinct kinetics of two pathologies induced in mice by topical treatment with imiquimod cream : Psoriasis-like inflammation and systemic autoimmunity. J Dermatol Sci. pii : S0923-1811 (18) 30214-17, 2018
 
8) Walter A, et al : Aldara activates TLR7-independent immune defence. Nat Commun 4 : 1560-1572, 2013
PubMed
9) Yokogawa M, et al : Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wildtype mice : a new model of systemic Lupus erythematosus. Arthritis Rheumatol 66 : 694-706, 2014
PubMed
10) Izui S, et al : Lessons from BXSB and related mouse models. Int Rev Immunol 19 : 447-472. 2000
 
11) Subramanian S, et al : A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 103 : 9970-9975, 2006
 
12) Pisitkun P, et al : Autoreactive B cell responses to RNArelated antigens due to TLR7 gene duplication. Science 312 : 1669-1672, 2006
PubMed
13) Bolland S, et al : Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB (-/-) mice. J Exp Med 195 : 1167-1174, 2002
PubMed
14) Amano H, et al : The Yaa mutation promoting murine lupus causes defective development of marginal zone B cells. J Immunol 170 : 2293-2301, 2003
 
15) Deane JA, et al : Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27 : 801-810, 2007
PubMed
P.157 掲載の参考文献
1) 小鍛治知子, ほか : 薬剤により皮疹が誘発されたサイトメガロウイルス単核症の1例. 臨皮 52 : 789-792, 1998
 
2) Sutkowski N, et al : Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 15 : 579-589, 2001
PubMed
3) 遠藤幹夫, ほか : アンピシリン疹を伴った伝染性単核球症, 臨皮 29 : 467-472 , 1975
 
4) Renn CN, et al : Amoxicillin-induced exanthema in young adults with infectious mononucleosis : demonstration of drug-specific lymphocyte reactivity. Br J Dermatol 147 : 1166-1170, 2002
PubMed
5) Saito-Katsuragi M, et al : Ampicillin-induced cutaneous eruption associated with Epstein-Barr virus reactivation. J Am Acad Dermatol 52 (suppl 1) : S127-128, 2005
 
P.162 掲載の参考文献
1) Chen P, et al : Carbamazepine-induced toxic effects and HLA-B* 1502 screening in Taiwan. N Engl J Med 364 : 1126-1133, 2011
PubMed
2) Ozeki T, et al : Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20 : 1034-1041, 2011
PubMed
3) Chung WH, et al : Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312 : 525-534, 2014
PubMed
4) Pichler WJ, et al : Drug hypersensitivity : flare-up reactions, cross-reactivity and multiple drug hypersensitivity. J Dermatol 38 : 216-221, 2011
PubMed
5) Illing PT, et al : Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486 : 554-558, 2012
PubMed
6) Takahashi R, et al : Defective regulatory T cells in patients with severe drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 : 8071-8079, 2009
PubMed
7) Saito N, et al : An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med 6 : 245ra95, 2014
PubMed
8) Wang CW, et al : Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 128 : 985-996, 2018
 
P.169 掲載の参考文献
1) Husain Z, et al : DRESS syndrome : Part I. Clinical perspectives. J Am Acad Dermatol 68 : 693.e1-4, 2013
 
2) Cho YT, et al : Co-existence of histopathological features is characteristic in drug reaction with eosinophilia and systemic symptoms and correlates with high grades of cutaneous abnormalities. J Eur Acad Dermatol Venereol 30 : 2077-2084, 2016
PubMed
3) Gowani F, et al : Drug-Induced Hypersensitivity Syndrome : A Clinical, Radiologic, and Histologic Mimic of Lymphoma. Case Rep Hematol : 2018 : 7037352, 2018
PubMed
4) Mizukawa Y, et al : Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score : A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol 80 : 670-678, 2019
 
5) Kano Y, et al : Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms : survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol 42 : 276-282, 2015
 
6) Hashizume H, et al : Reciprocal contribution of Th17 and regulatory T cells in severe drug allergy. J Dermatol Sci 81 : 131-134, 2016
PubMed
7) Takahashi R, et al : Defective regulatory T cells in patients with severe drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 : 8071-8079, 2009
PubMed
8) Ogawa K, et al : Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS) /drug rash with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci 69 : 38-43, 2013
 
9) Ogawa K, et al : Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS) /drug-induced hypersensitivity syndrome (DIHS). Br J Dermatol 171 : 425-427, 2014
PubMed
10) Niu J, et al : Association of CD8 (+) T lymphocyte repertoire spreading with the severity of DRESS syndrome. Sci Rep 5 : 9913, 2015
PubMed
11) Picard D, et al : Drug reaction with eosinophilia and systemic symptoms (DRESS) : a multiorgan antiviral T cell response. Sci Transl Med 2 : 46ra62, 2010
 
12) Ushigome Y, et al : Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Clin Exp Allergy 48 : 1453-1463, 2018
PubMed
13) Hashizume H, et al : Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy. Allergy 68 : 681-689, 2013
PubMed
14) Miyagawa F, et al : Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS) /drug reaction with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci 83 : 151-154, 2016
 
15) Shiohara T, et al : Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol Int 59 : 333-343, 2010
PubMed
16) Yoneda S, et al : A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation. J Clin Endocrinol Metab 102 : 2394-2400, 2017
PubMed
P.174 掲載の参考文献
1) Mackay LK, et al : The developmental pathway for CD103 (+) CD8 (+) tissue-resident memory T cells of skin. Nat Immunol 14 : 1294-1301, 2013
PubMed
2) Park CO, Kupper TS : The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Immunol 21 : 688-697, 2015
 
3) Sallusto F, et al : A two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 : 708-712, 1999
 
4) Clark RA, et al : Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 4 : 117, 2012
 
5) Watanabe R, et al : Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma : diffuse erythema as appositive predictor of complete remission. JAMA Dermatol 150 : 776-779, 2014
 
6) Mizukawa Y, et al : Direct evidence for IFN-g production by effector-memory type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 161 : 1337, 2002 :
PubMed
7) Shiohara T : Fixed drug eruption : pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 9 : 316, 2009
PubMed
8) Mizukawa Y, Shiohara T : A prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 9 : 71, 2009
PubMed
9) Cho YT, et al : Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 70 : 539-548, 2014
PubMed
10) Rai R, et al : Multifocal bullous fixed drug eruption mimicking Stevens-Johnson syndrome. Indian J Dermatol Venereol Leprol 68 : 175-6, 2002
PubMed
11) 水川良子, 狩野葉子 : 口唇に生じる固定薬疹. Derma 251 : 22-28, 2016
Medical*Online
12) Mizukawa Y, Shiohara T : Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis : immunohistochemical and serum cytokine analyses. Clin Exp Dermatol 35 : 493-497, 2010
PubMed
13) Mizukawa Y, et al : In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 158 : 1230-1238, 2008
PubMed
14) Cheuk S, et al : CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. Immunity 46 : 287-300, 2017
PubMed
15) Mizukawa Y, Shiohara T : Trauma-localized fixed drug eruption : involvement of burn scars, insect bites and venipuncture. Dermatology 205 : 159-161, 2002
PubMed
16) Adachi T, et al : Hair follicule-derived IL-7 and IL-15 mediate skin-resident memory T cells homeostasis and lymphoma. Nat Med 43 : 1272-1279, 2015
 

書評

最近チェックした商品履歴

Loading...